Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 14 Diseases   2 Trials   2 Trials   176 News 


1234»
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), 177Lu-DOTA-girentuximab (TLX250) / Telix, 177Lu-rosopatamab tetraxetan (TLX591) / Telix
    Evaluation of tumour-targeting fusion proteins that antagonize TGF-β in the tumour microenvironment via simultaneous binding to CAIX or PSMA and TGF-β (Exhibit Hall D - Science Pavilion (Convention Center); Screen 45; In-Person Only) -  May 8, 2024 - Abstract #SNMMI2024SNMMI_818;    
    Given that the parent antibodies from which these traps are derived are in development as radiopharmaceuticals, the TLX TGF-? traps present an opportunity to enhance anti-tumour immunity by delivering radiotherapy to metastatic disease, while simultaneously mitigating the immunosuppressive properties of TGF-?.
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
    Radiation Protection Considerations with 89Zr-girentuximab PET/CT (Exhibit Hall D - Science Pavilion (Convention Center); Screen 15; In-Person Only) -  May 8, 2024 - Abstract #SNMMI2024SNMMI_660;    
    Given that the patient studied underwent radical nephrectomy only 4 days after 89Zr-girentuximab administration, with patient surgery occurring 20. 5
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Phase 1b/2 study of combination 177 Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC. (Hall A; Poster Bd #: 303b) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1775;    
    P1/2
    The combination of nivolumab plus cabozantinib was recently approved for the first-line treatment of ccRCC based on the CheckMate 9ER phase 3 study demonstrating improved progression-free survival (PFS) and objective response rate (ORR) in comparison to sunitinib...Starting with the second cycle, nivolumab and cabozantinib will be added at standard dose. To explore the effects of the treatment on inducing activated T cell infiltration, patients will undergo pre/post-treatment PET scan with 18 F-AraG radiotracer as well as biopsies for single cell, spatial transcriptomics and proteomics studies.
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
    Journal:  Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX. (Pubmed Central) -  Mar 1, 2024   
    This new H2MacropaSqOEt chelator was used to modify a monoclonal antibody, girentuximab (hG250), that binds to carbonic anhydrase IX, an enzyme that is overexpressed on the surface of cancers such as clear cell renal cell carcinoma...Evaluation of [225Ac]Ac(MacropaSq-hG250) in a mouse xenograft model, that overexpresses carbonic anhydrase IX, demonstrated a highly significant therapeutic response. It is likely that H2MacropaSqOEt could be used to modify other antibodies providing a readily adaptable platform for other actinium-225 based therapeutics.
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Enrollment closed, Phase classification, Metastases:  Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=100, Active, not recruiting, 
    It is likely that H2MacropaSqOEt could be used to modify other antibodies providing a readily adaptable platform for other actinium-225 based therapeutics. Suspended --> Active, not recruiting | Phase classification: P2 --> P1/2
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Trial suspension, Metastases:  Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na (clinicaltrials.gov) -  Jan 12, 2024   
    P2,  N=100, Suspended, 
    Suspended --> Active, not recruiting | Phase classification: P2 --> P1/2 Recruiting --> Suspended
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC. (Level 1, West Hall; Poster Bd # M17) -  Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_693;    
    P2
    The combination of nivolumab plus cabozantinib was recently approved for the first-line treatment of ccRCC based on the CheckMate 9ER phase 3 study demonstrating improved progression-free survival (PFS) & objective response rate (ORR) in comparison to sunitinib...To explore the effects of the treatment on inducing activated T cell infiltration, patients will undergo pre/post-treatment PET scan with [18F]F-AraG radiotracer as well as biopsies for single cell, spatial transcriptomics and proteomics studies. Clinical trial information: NCT05239533.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  STARLITE 2: Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer (clinicaltrials.gov) -  Dec 4, 2023   
    P2,  N=41, Recruiting, 
    Clinical trial information: NCT05239533. N=29 --> 41 | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Enrollment open, Trial initiation date, Metastases:  Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na (clinicaltrials.gov) -  Jul 7, 2023   
    P1b/2,  N=100, Recruiting, 
    These findings suggest that S100P could serve as a promising biomarker for immunosuppressive microenvironment, which may provide a novel therapeutic way for pancreatic cancer. Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Jun 2023
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Trial initiation date, Metastases:  Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na (clinicaltrials.gov) -  Jul 3, 2023   
    P1b/2,  N=100, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Jun 2023 Initiation date: May 2023 --> May 2024
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Prometheus
    Review, Journal:  Insights into Renal Cell Carcinoma with Novel Imaging Approaches. (Pubmed Central) -  Jun 11, 2023   
    Additionally, newer modalities, such as contrast-enhanced ultrasound, dual energy computed tomography, and molecular imaging, will be discussed in conjunction with emerging radiomics and artificial intelligence techniques. Current diagnostic algorithms combined with newer approaches may be an effective way to overcome existing limitations in renal mass and RCC characterization.
  • ||||||||||  Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Prometheus, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment na (On Demand | Hall A; Poster Bd # 95a) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_2105;    
    The combination of nivolumab plus cabozantinib was recently approved for the first-line treatment of ccRCC based on the CheckMate 9ER phase III study demonstrating improved progression-free survival (PFS) and objective response rate (ORR) in comparison to sunitinib...After the first cycle, nivolumab and cabozantinib will be added starting with the second cycle at standard dose. To explore the effects of the combination therapy on inducing activated T cell infiltration, patients will undergo pre/post-treatment PET scan with [18F]F-AraG radiotracer as well as biopsies for single cell, spatial transcriptomics and proteomics studies.
  • ||||||||||  Trial completion, Trial completion date:  89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (clinicaltrials.gov) -  Apr 14, 2023   
    P3,  N=300, Completed, 
    Initiation date: Nov 2022 --> May 2023 Active, not recruiting --> Completed | Trial completion date: May 2023 --> Nov 2022